1-乙酰基-3-(4-氟苯甲酰基)哌啶-4-酮 | 87642-26-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-乙酰基-3-(4-氟苯甲酰基)哌啶-4-酮
• 英文名称: 4-Piperidinone, 1-acetyl-3-(4-fluorobenzoyl)-
• 英文别名: 1-acetyl-3-(4-fluorobenzoyl)piperidin-4-one
• CAS: 87642-26-0
• 化学式: C₁₄H₁₄FNO₃
• 分子量: 263.268
• InChiKey: MTDHSCZHLWJVIF-UHFFFAOYSA-N

物化性质

• 沸点：
  402.3±45.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-乙酰基-3-(4-氟苯甲酰基)哌啶-4-酮 在 盐酸 、 sodium hydride 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 7.5h， 生成 3-(4-Fluorophenyl)-1-pentyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine
  参考文献：
  名称：

  Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents

  摘要：

  A series of new 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines was synthesized and screened for in vitro [3H]prazosin displacement activity. The results correlated well with their antihypertensive activity in spontaneous hypertensive rats. 1-Benzyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyrid ine (50, L 16052) was selected for further pharmacological evaluations of its potency when administered orally to conscious renal hypertensive dogs.

  DOI：

  10.1021/jm00145a015
• 作为产物：
  描述：

  N-乙酰基-4-哌啶酮 在 对甲苯磺酸 、 三乙胺 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 28.0h， 生成 1-乙酰基-3-(4-氟苯甲酰基)哌啶-4-酮
  参考文献：
  名称：

  Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents

  摘要：

  A series of new 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines was synthesized and screened for in vitro [3H]prazosin displacement activity. The results correlated well with their antihypertensive activity in spontaneous hypertensive rats. 1-Benzyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyrid ine (50, L 16052) was selected for further pharmacological evaluations of its potency when administered orally to conscious renal hypertensive dogs.

  DOI：

  10.1021/jm00145a015

文献信息

• Pharmacologically active pyrazolo(4,3-c)pyridines
  申请人：GRUPPO LEPETIT S.p.A.

  公开号：EP0086422A2

  公开（公告）日：1983-08-24

  The present invention is directed to new pyrazolo/4,3- c/pyridines, the process for their preparation, the pharmaceutical compositions containing them and their use as pharmocologically active substances. The compounds of the invention possess cardiotonic, antihypertensive, CNS depressant, neuroleptic, and analgesic activity.

  本发明涉及新的吡唑/4,3-c/吡啶、其制备工艺、含有它们的药物组合物以及它们作为药理活性物质的用途。 本发明的化合物具有强心、降压、中枢神经系统抑制、神经抑制和镇痛活性。
• US4500525A
  申请人：——

  公开号：US4500525A

  公开（公告）日：1985-02-19
• Novel tetrahydropyrido[4,3-d]pyrimidines as gastric antilesion agents
  作者：PJ Sanfilippo、M Urbanski、L Williams、JB Press、LB Katz、DA Shriver、JA Fernandez、D Shatynski、SJ Offord

  DOI：10.1016/0223-5234(92)90085-f

  日期：1992.10

  A variety of substituted tetrahydropyrido[4,3-d]pyrimidines was prepared and found to possess gastric antilesion against ethanol-induced lesions in rats. The more potent compounds possessed similar activity against aspirin-induced gastric lesions. A selective group of compounds was determined to be inactive as gastric antisecretory agents in rabbit isolated parietal cells. The antilesion properties of these tetrahydropyrido[4,3-d]pyrimidines make them a potential alternative to prostaglandin therapy for gastric antilesion therapy and may have clinical utility in peptic ulcer disease.
• Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents
  作者：Giorgio Winters、Alberto Sala、Domenico Barone、Emiliana Baldoli

  DOI：10.1021/jm00145a015

  日期：1985.7

  A series of new 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines was synthesized and screened for in vitro [3H]prazosin displacement activity. The results correlated well with their antihypertensive activity in spontaneous hypertensive rats. 1-Benzyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyrid ine (50, L 16052) was selected for further pharmacological evaluations of its potency when administered orally to conscious renal hypertensive dogs.